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Objectives: Baseline data from the Morquio A Clinical Assessment Program (MorCAP) revealed that individuals
with Morquio A syndrome show substantial impairment in multiple domains including endurance and respira-
tory function (Harmatz et al.,MolGenetMetab, 2013). Here, 1- and 2-year longitudinal endurance and respiratory
function data are presented.
Methods: Endurance was assessed using the 6-minute walk test (6MWT) and the 3-minute stair climb test
(3MSCT). Respiratory function was evaluated by measuring forced vital capacity (FVC) and maximum voluntary
ventilation (MVV). Data were analyzed using repeated measures ANCOVA models. Annualized estimates of
change were determined using model estimates and interpolation.
Results: 353, 184, and 78 subjects were assessed at Year 0 (baseline), Year 1, and Year 2, respectively. The overall
annualized estimate of change (SE) in 6MWT distance was−4.86± 3.25 m; a larger decline of−6.84 ± 5.38m
was observed in the subset of subjects meeting the inclusion/exclusion criteria of the Phase 3 clinical trial of
elosulfase alfa (≥5 years of age with baseline 6MWT distance ≥30 and ≤325 m). In contrast, little change
(−0.14 ± 0.60 stairs/min) was observed in 3MSCT. Annualized changes (SE) in FVC and MVV were 2.44 ±
0.68% and 1.01 ± 2.38%, respectively. FVC and MVV increased in patients aged ≤14 years, but decreased in
older patients.
Conclusions: The natural history of Morquio A syndrome is characterized by progressive impairment of endur-
ance as measured by the 6MWT. Longitudinal trends in FVC and MVV showing increase in younger patients,
but decrease in older patients, are likely to be inﬂuenced by growth. Changes in 6MWTmay represent a sensitive
measure of disease progression in ambulatory Morquio A patients.© 2014 BioMarin Pharmaceutical Inc. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).alifornia 94949, USA.
d by Elsevier Inc. This is an open acc
es/by-nc-nd/3.0/).1. Introduction
Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA), is a
rare lysosomal storage disorder caused by deﬁcient activity of N-acetyl-ess article under the
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cosaminoglycans (GAG) keratan sulfate and chondroitin-6-sulfate. In-
tracellular GAG accumulation leads to the development of
multisystemic impairments, including short stature, skeletal deformi-
ties, joint abnormalities, obstructive and restrictive respiratory disease,
and cardiac valve disease [1–7]. Over 275 GALNS mutations have been
identiﬁed, resulting in wide phenotypic heterogeneity [5,8–12]. Life ex-
pectancy is shortened, with survival often limited to the second or third
decade in patients with “classical phenotype”, but ranging up to and
beyond 60 years in a few patients [1,4,5]. Death is commonly due to
cardiorespiratory or neurological complications [1,4,13]. The manage-
ment of Morquio A syndrome has until recently been limited to sup-
portive and symptom-based care, but enzyme replacement therapy
(ERT) with elosulfase alfa has now become available as a treatment
option [14].
The natural history of Morquio A syndrome is currently not well
deﬁned. Characterization of the range and progression of symptoms
across a large subject population is expected to lead to improved under-
standing andmanagement of the disorder. TheMorquio A International
Registry has published information about the manifestations and natu-
ral course of Morquio A syndrome based on self-reported question-
naires obtained from 326 patients [1]. However, clinical evaluations
are required to better characterize the natural course of this condition.
TheMorquio A Clinical Assessment Program (MorCAP) is a multicenter,
multinational, longitudinal natural history study designed to describe
the spectrum and progression of symptoms in untreated Morquio A
syndrome through direct clinical observation and assessments [2].
Baseline data collected from the ﬁrst 325 patients enrolled in MorCAP
demonstrated substantial impairment in multiple domains including
endurance, mobility, respiratory function and growth [2]. Musculoskel-
etal manifestations, including short stature, abnormal gait, genu valgum
and pectus carinatum, were reported in more than 90% of MorCAP
patients and contribute to the observed functional limitations.
Wheelchair andwalk aid usewere found to be common amongMorCAP
subjects.
Submaximal intensity endurance tests such as the 6-minute walk
test (6MWT) assess cardiorespiratory and musculoskeletal function
and are recognized as clinically meaningful outcome measures in MPS
disorders [15–19]. The 6MWT was used as the primary measure of
efﬁcacy in the Phase 3 randomized, double-blind, placebo-controlled
clinical trial of elosulfase alfa, in which a statistically signiﬁcant
improvement of 22.5 m in 6MWT distance over placebo was demon-
strated at 24 weeks [20]. The 3-minute stair climb test (3MSCT) was a
secondary endpoint in this study but did not show statistically signiﬁ-
cant improvement with treatment [20]. In addition to endurance
measures, respiratory function tests have also been included as efﬁcacy
endpoints in ERT studies for MPS disorders including Morquio A syn-
drome [16,17,20,21]. MorCAP baseline data revealed severe limitations
in walking and stair climbing ability among subjects, with mean
6MWT distance of 212.6 ± 152.2 m and mean 3MSCT of 30.0 ±
24.0 steps/min [2]. Respiratory function was also severely compro-
mised in the MorCAP population, with mean forced vital capacity
(FVC) of 1.2 ± 0.9 L and mean maximum voluntary ventilation (MVV)
of 34.8 ± 25.5 L/min [2]. This present study reports the functional
endurance and respiratory function data obtained from MorCAP
subjectswhowere followed for aminimumof 1 year andwho completed
assessments at the 1 year and/or 2 year follow-up visit(s).
2. Methods
2.1. Patients
MorCAP is a multicenter, multinational, observational study of indi-
viduals withMorquio A syndrome. Eligibility criteria for participation in
MorCAP were described previously [2]. Brieﬂy, individuals with docu-
mented reduced GALNS enzyme activity (relative to the normal rangeof the laboratory performing the assay) or genetic testing conﬁrming a
diagnosis of Morquio A syndrome were eligible. Individuals with a
previous hematopoietic stem cell transplant (HSCT) or with a concur-
rent disease or condition that would interfere with study participation
or pose a safety concern were excluded. The study was approved by
all institutional review boards and ethics committees. Subjects gave
written informed consent, or, in the case of subjects aged b18 years,
written consent was obtained from a legally authorized representative.
Subjects were free to enroll in ERT or other clinical trials but were no
longer eligible to continue participation in the MorCAP study once this
occurred.
2.2. Assessments
The 6MWT [22] and 3MSCT [23] were performed according to
published guidelines. Respiratory function was evaluated based on
measurements of forced expiratory time (FET), forced expiratory
volume for 1 s (FEV1), forced inspiratory vital capacity (FIVC), FVC,
and MVV. These tests were conducted in accordance with the
American Thoracic Society standards [24]. In the present study, FVC
and MVV were selected as the most relevant respiratory function
assessments for analysis; FVC is indicative of the degree of restrictive
lung diseasewhileMVV is ameasure of airway resistance and respirato-
ry muscle strength. Sites were provided with scheduling recommenda-
tions to ensure that patients received adequate rest between effort-
based procedures. The study was initiated as a cross sectional study
with only one visit per subject. The study was later amended to capture
longitudinal data and this present analysis includes data from visits at
baseline (Year 0), Year 1 and Year 2. Since subjects enrolled at variable
calendar time and the amendment was initiated at a ﬁxed time, the
timing between visits at baseline and Year 1 varied by subject.
2.3. Statistical analysis
Baseline demographics and characteristics were summarized for all
subjects who completed the Year 1 visit assessments and for subjects
who completed the Year 2 visit assessments. Similar summaries were
applied to the subset of subjectsmeeting the inclusion/exclusion criteria
of the Phase 3 clinical trial of elosulfase alfa, i.e.≥5 years of age at base-
line with a baseline 6MWT distance ≥30 and ≤325 m [20], in order to
assess disease progression in subjects similar to those undergoing
experimental ERT. Limits for baseline 6MWT distance were applied to
subjects in the pivotal Phase 3 study to evaluate those who were most
likely to show improvement with treatment, i.e. the lower limit enabled
exclusion of severely walk-impaired patients while the upper limit
allowed exclusion of those subjects with walk distance approaching
the normal range to avoid the potential for a ceiling effect [20].
The longitudinal data were summarized by visit. Because the
timing between visits at baseline and Year 1 varied by subject, the
windows were deﬁned in order to capture the most data. The visit at
baseline was deﬁned as day 1; Year 1 visits included assessments
collected between days 270 and 609 (approximately month 9 to 20,
centered at day 439.5); Year 2 visits included assessments collected
between days 610 and 944 (approximately month 21 to 31, centered
at day 777).
Subjects who were physically unable to perform the functional
endurance tests (6MWT and 3MSCT) had the functional tests scored
as 0. Any other missing data were not imputed. Repeated measures
ANCOVA models were used to estimate the change from baseline to
Year 1 and Year 2 for 6MWT and 3MSCT and percent change from base-
line to Year 1 and Year 2 for FVC andMVV assessments. For the analysis
of change in 6MWT to Year 1 and Year 2, the model included analysis
visit (Year 1 and Year 2), age group (0–4, 5–11, 12–18, ≥19 years),
and baseline 6MWT category (0–b30, 30–≤200, N200–≤325, and
N325 m) as factors, using unstructured variance. The analyses for
3MSCT, FVC andMVVused a similarmodelwith the additional covariate
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between baseline and Year 1 was 444 days, and between Year 1 and
Year 2 was 352 days. Annualized estimates were obtained using the
model estimates at Year 1 and Year 2 and interpolation. Changes in
respiratory parameters were correlated with changes in endurance
parameters.
3. Results
3.1. Patient characteristics
Baseline characteristics of the ﬁrst 325 subjects enrolled in MorCAP
have been published previously [2]. In the present study, baseline
characteristics were summarized by duration of follow-up and the
criteria of the Phase 3 clinical trial. Of the 353 subjects with data at
baseline, 184 were followed to the Year 1 evaluation or later and 78Table 1
Baseline demographics and characteristics of subjects.
All subjects
With Year 1 follow-up With Year 2
N 184 78
Female 100 (54.3%) 37 (47.4%)
Age at enrollment (years)
n 184 78
Mean (SD) 14.4 (11.97) 15.4 (13.48)
Median 11.0 11.0
Min, max 1.0, 65.0 1.0, 65.0
0–4 28 (15.2%) 9 (11.5%)
5–11 77 (41.8%) 35 (44.9%)
12–18 36 (19.6%) 17 (21.8%)
Over 18 43 (23.4%) 17 (21.8%)
Standing height (cm)
n 163 66
Mean (SD) 104.1 (16.82) 105.1 (15.96
Median 99.5 101.0
Min, max 81.4, 171.5 82.0, 171.5
Weight (kg)
n 184 78
Mean (SD) 24.5 (12.85) 25.9 (14.48)
Median 21.40 22.30
Min, max 10.2, 110.6 10.6, 110.6
6 MWT distance (m)
n b 147 66
Mean (SD) 209.0 (132.59) 197.2 (131.3
Median 220.5 209.5
Min, max 0.0, 531.0 0.0, 418.5
3 MSCT (steps/min)
n b 134 55
Mean (SD) 30.3 (21.93) 27.0 (18.88)
Median 28.9 24.30
Min, max 0.0, 85.6 0.0, 73.5
FVC (L)
n b 122 49
Mean (SD) 1.1 (0.76) 1.2 (0.78)
Median 0.90 1.0
Min, max 0.3, 4.7 0.2, 4.9
MVV (L/min)
n b 106 44
Mean (SD) 32.2 (19.09) 34.7 (25.33)
Median 26.5 28.2
Min, max 7.0, 107.0 10.3, 160.0
Urine KS (μg/mg) c
n 180 78
Mean (SD) 37.57 (27.24) 36.46 (23.53
Median 32.55 35.15
Min, max 0.94, 168.10 2.30, 102.70
Abbreviations: 6 MWT = 6 minute walk test; 3 MSCT = 3 minute stair climb test; FVC = for
a Phase 3-matched subjects are those subjects whomet the inclusion/exclusion criteria of th
≥30 and ≤325 m.
b Only subjects with both baseline and follow-up data were included.
c Normalized urine KS values (calculated as urine KS divided by urine creatinine).were followed to the Year 2 visit or later. Of the subset of patients
who were ≥5 years of age with a baseline 6MWT distance of ≥30 and
≤325 m (the Phase 3-matched subjects), 97 were followed to Year 1
or later and 40were followed to Year 2 or later. Therewere fewer obser-
vations at later visits due to a number of reasons:
• the later visits had not yet occurred for later accruals
• 123 subjects discontinued from MorCAP in order to enroll in ERT
clinical trials
• subjects missed visits, or were discontinued for other reasons
Table 1 summarizes the baseline demographics and characteristics
of the groups of subjects under evaluation. Baseline height, gender,
endurance and respiratory function were similar across groups. The
baseline mean age was slightly higher and the 6MWT ranges were
narrower for the Phase 3-matched groups.Phase 3-matched subjects a
follow-up With Year 1 follow-up With Year 2 follow-up
97 40
56 (57.7%) 19 (47.5%)
97 40
16.3 (12.20) 17.0 (14.76)
11.0 11.0
1.0, 65.0 1.0, 65.0
– –
49 (50.5%) 21 (52.5%)
20 (20.6%) 9 (22.5%)
28 (28.9%) 10 (25.0%)
95 39
) 106.3 (14.16) 107.3 (12.60)
101.9 102.0
83.0, 150.5 90.0, 141.0
97 40
26.1 (10.28) 26.8 (10.73)
23.80 23.60
12.2, 67.0 12.2, 67.0
77 38
6) 201.8 (83.73) 206.7 (81.32)
206.9 218.3
30.0, 320.0 60.0, 325.0
72 33
30.7 (17.73) 28.7 (16.08)
28.00 24.3
0.0, 85.6 0.0, 60.4
71 32
1.2 (0.70) 1.2 (0.60)
0.9 1.0
0.3, 4.7 0.2, 2.5
63 29
32.9 (18.81) 31.5 (14.50)
26.6 29.9
7.0,103.0 10.3, 68.0
97 40
) 33.48 (25.64) 31.21 (18.61)
30.70 34.60
2.30, 168.10 2.30, 68.40
ced vital capacity; MVV = maximum voluntary ventilation; KS = keratan sulfate.
e Phase 3 clinical trial of elosulfase alfa, i. e. ≥5 years of age with baseline 6MWT distance
Fig. 1.Mean 6MWT distance versus age in MorCAP subjects aged ≤20 years.
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The majority of subjects within each group had an evaluable 6MWT
at both baseline and at follow-up. Among these subjects, 30 were
deemed physically unable to perform at least one 6MWT (scored as
0), the majority of whomwere unable to perform the test both at base-
line and all available follow-up; no reasons were given to explain the
inability to perform a test. Twenty one subjects used a walking aid
(cane, crutches, walking frame) during the test; changes in 6MWT
were similar between those who used walk aids and those who did
not. Several subjects were unable to complete a 6MWT due to pain
(13 subjects), fatigue (7 subjects) and shortness of breath (4 subjects).
At each visit, mean 6MWT distances were found to generally
decrease with increasing age (Fig. 1). Mean baseline 6MWT distances
for the groups of subjects under evaluation ranged from 197.2 m to
209.0 m (Tables 1 and 2). The least-square mean changes in 6MWT
distance from baseline are shown in Fig. 2 and are also summarized in
Table 2. Declines from baseline 6MWT distances were observed at
Year 1 and Year 2 and were more pronounced in the Phase 3-matched
subjects. The annualized estimate of change (SE) in 6MWT from base-
line across all subjects was−4.86 ± 3.25 m, while a greater decline of
−6.84 ± 5.38 m was determined for the Phase-3 matched subjects
(Table 2).Table 2
Summary of changes in 6MWT and 3MSCT.
Mean (SD)
baseline
6MWT (m)
All subjects
With Year 1 follow-up (n = 147) 209.0 (132.59)
With Year 2 follow-up (n = 66) 197.2 (131.36)
Phase 3-matched subjects
With Year 1 follow-up (n = 77) 201.8 (83.73)
With Year 2 follow-up (n = 38) 206.7 (81.32)
3MSCT (steps/min)
All subjects
With Year 1 follow-up (n = 134) 30.3 (21.93)
With Year 2 follow-up (n = 55) 27.0 (18.88)
Phase 3-matched subjects
With Year 1 follow-up (n = 72) 30.7 (17.73)
With Year 2 follow-up (n = 33) 28.7 (16.08)Most subjects within each group had an evaluable 3MSCT at both
baseline and at follow-up. Of these subjects, 34 were considered physi-
cally unable to perform at least one 3MSCT (scored as 0); no reasons
were given to explain an inability to perform the test. Some subjects
were unable to complete a 3MSCT due to pain (4 subjects), fatigue
(9 subjects) and shortness of breath (3 subjects).
Mean baseline 3MSCT for the groups ranged from 27.0 to 30.7 steps/
min (Tables 1 and 2). The least-square mean changes in 3MSCT were
small, ranging from−0.02 to−0.61 steps/min (Table 2). The annual-
ized estimate of change (SE) in 3MSCT from baseline was −0.14 ±
0.60 steps/min across all subjects and−0.30 ± 0.99 steps/min for the
Phase 3-matched subjects (Table 2).
3.3. FVC and MVV
Pulmonary function reference values are derived from individuals of
normal stature, and therefore the utility of these values is unclear for
individuals with severe short stature. Additionally, it is difﬁcult to
accurately assess height in these patients due to their severe skeletal
dysplasia (severe genu valgum, scoliosis, etc.). For these reasons, FVC
andMVV changeswere analyzed in terms of percent change in absolute
volumes rather than as percent predicted values. Mean percent changes
from baseline FVC (1.1–1.2 L) and baseline MVV (31.5–34.7 L/min) areLeast square mean (SE)
change from baseline
Annualized change (SE)
−4.86 (3.25)
−3.92 (5.118)
−9.72 (6.499)
−6.84 (5.38)
−5.81 (7.868)
−13.67 (10.762)
−0.14 (0.603)
−0.02 (0.761)
−0.28 (1.206)
−0.30 (0.987)
−0.61 (1.222)
−0.60 (1.974)
Fig. 2.Mean 6MWT changes from baseline for MorCAP subjects.
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alized estimates of change (SE) in FVC andMVVwere 2.44± 0.68% and
1.01 ± 2.38%, respectively, across all subjects, and 2.39 ± 0.75% and
0.10 ± 2.69%, respectively, for the Phase 3-matched subjects
(Table 3). Further analysis revealed that the longitudinal changes in
these respiratory function parameters were age-dependent: FVC and
MVV increased in subjects who were aged ≤14 years at baseline but
decreased in older patients (Fig. 3). Changes in FVC or MVV did not
correlate with changes in 6MWT (Fig. 4).
4. Discussion
Insight into the natural history of Morquio A syndrome is expected
to guide clinical management strategies. Cross-sectional analysis of
325 MorCAP subjects at baseline demonstrated signiﬁcant limitations
in endurance and respiratory function and showed that impairments
in 6MWT, 3MSCT, FVC and MVV were generally more severe in older
patients [2]. Findings from this longitudinal analysis provide further
evidence that untreated Morquio A syndrome is progressive and
characterized by gradual decline in endurance and respiratory function
parameters.
The 6MWT (or 12MWT as a variation) provides a simple and sensi-
tive measure of the functional capacity of MPS patients and has beenTable 3
Summary of changes in FVC and MVV.
Mean (SD)
baseline
FVC (L)
All subjects
With Year 1 follow-up (n = 122) 1.1 (0.76)
With Year 2 follow-up (n = 49) 1.2 (0.78)
Phase 3-matched subjects
With Year 1 follow-up (n = 71) 1.2 (0.70)
With Year 2 follow-up (n = 32) 1.2 (0.60)
MVV (L/min)
All subjects
With Year 1 follow-up (n = 106) 32.2 (19.09)
With Year 2 follow-up (n = 44) 34.7 (25.33)
Phase 3-matched subjects
With Year 1 follow-up (n = 63) 32.9 (18.81)
With Year 2 follow-up (n = 29) 31.5 (14.50)used as a primary outcome measure or component of a composite out-
come measure in ERT clinical trials for MPS I, II, and VI, as well as
Morquio A syndrome [16–20]. Mean baseline 6MWT distances for the
subjects analyzed in this study were at least 2- to 3-fold below the
lower limits of age-speciﬁc normal ranges reported for healthy children
and adolescents [25–28] and for healthy adults [22,29]: one study
reported a mean 6MWT distance of 470 ± 59 m for healthy boys and
girls aged 4–11 years [26], while another reported a mean 6MWT
distance of 618 ± 79 m for healthy children and adolescents aged
5–17 years [28]; for adults, mean 6MWT distances of 593 ± 57 m and
638 ± 44 m have been reported for healthy women and men, respec-
tively [29]. The mean walk distances of MorCAP subjects were also con-
siderably lower than those reported for populations of untreated
patients with MPS I (319.1 ± 131.4 m to 366.7 ± 113.7 m), MPS II
(392 ±107 m to 401 ± 102 m), and MPS VI (273.1 ± 137.03 m) [16,
17,30], and reﬂect the greater degree of musculoskeletal involvement
in Morquio A patients. Moreover, mean 6MWT distance generally de-
creased with age, corroborating the ﬁndings from the cross-sectional
analysis [2]; this trend is in sharp contrast to what is expected in unaf-
fected populations of healthy children and adolescents [25,26,28].
A general decline in 6MWT distance from baseline was observed across
all subjects over the course of this 2-year longitudinal study, indicating
thatMorquioA syndrome is characterized byprogressive impairment inLeast square mean % change (SE)
from baseline
Annualized % change (SE)
2.44 (0.678)
2.05 (1.012)
4.88 (1.357)
2.39 (0.747)
2.10 (1.261)
4.78 (1.493)
1.01 (2.376)
3.65 (4.506)
2.02 (4.752)
0.10 (2.692)
1.77 (4.114)
0.19 (5.384)
FVC 
MVV 
Fig. 3. FVC and MVV changes in MorCAP subjects stratiﬁed by baseline age ≤14 years and N14 years.
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mobility declines and wheelchair dependence increases [31]. While
further study will be required to determine the exact mechanisms
underlying the observed decline in walking ability, the results from
this study demonstrate the utility of the 6MWT as a clinically meaning-
ful measure of disease progression in ambulatory Morquio A patients.
It is unclear why a similar change in 3MSCT was not observed. It is
possible that this test may not be suitable for Morquio A patients, who
typically have severe skeletal dysplasia, short stature and joint involve-
ment that considerably limit the ability to climb stairs. Difﬁculties with
standardizing stair height and stairwell conﬁguration may have also
inﬂuenced the data.
Subjects showed signiﬁcant impairment in respiratory function at
baseline, with absolute FVC and MVV volumes comparable to those
reported for other MPS disorders [17,30,32] and well below those
reported for healthy subjects of normal stature [33–35]. The respiratoryfunction compromise may be attributed to the combined effects of
multiple abnormalities including short stature, altered chest wall
shape and size, and airway obstruction [36]. While an overall upward
trend was observed in respiratory function, the longitudinal changes
in FVC and MVV were found to be dependent on age. Growth-related
factors (height increase, thoracic enlargement) likely inﬂuence the
observed patterns of change as FVC and MVV increased in patients
with baseline age≤14 years but decreased in older patients. In healthy
children and adolescents, lung function measurements increase with
height, with the greatest increase occurring during puberty [33]. It is
likely, therefore, that overall declines in FVC and MVV will be observed
in MorCAP subjects over a longer period of follow-up.
To better understand why the decline observed in 6MWT was not
reﬂected in the respiratory function tests, an analysis of the correlation
between these parameters was performed. No correlations between
changes in 6MWT and respiratory function parameters were found in
Fig. 4. Scatter plots of (a) percent change of FVC and change in 6MWT and (b) percent change of MVV and change in 6MWT. Data shown are for Year 1.
192 P.R. Harmatz et al. / Molecular Genetics and Metabolism 114 (2015) 186–194this study. This could be due to the fact that ventilatory demands are
different in the 6MWT and respiratory function tests. The 6MWT is a
submaximal exercise capacity test while FVC and MVV assessments
require maximum effort. Alternatively, the 6MWT is multi-factorial
and the observed decline may be predominantly driven by factors
other than respiratory limitations. It is noteworthy that several (13)
subjects could not complete the 6MWT due to pain, suggesting that
the inﬂuence of musculoskeletal impairment is signiﬁcant. Other
reasons cited for incompletion of a 6MWT were fatigue and shortness
of breath. Longer duration of follow-up as well as inclusion of assess-
ments of pain, fatigue, shortness of breath and other relevant physical
factors before and after testing are likely to yield more insight into the
determinants of the observed decline in 6MWT distance.There were several limitations associated with this study. Many
subjects left the MorCAP study to enroll in ERT clinical trials, resulting
in a smaller study population and less precise estimates of endurance
and respiratory changes. Limited assessments were conducted before
and after the 6MWT; formal evaluations of pain or fatigue, for example,
could have been helpful in elucidating themechanisms for the observed
decline. Due to the degree of respiratory compromise in this population,
some recorded values may have been a result of unsatisfactory effort.
While the scope of this study was limited to focus on key clinical end-
points relevant to the ERT trials, future analyses are planned to analyze
other parameters collected inMorCAP aswell as to deﬁne possible asso-
ciations between urinary keratan sulfate levels and changes in clinical
parameters. Longer follow-up and further analyses will be needed to
193P.R. Harmatz et al. / Molecular Genetics and Metabolism 114 (2015) 186–194identify the factors that inﬂuence longitudinal trends in endurance and
respiratory function parameters.
5. Conclusions
Untreated Morquio A syndrome is characterized by progressive
decline in endurance as measured by the 6MWT. Changes in 6MWT
may represent a sensitivemeasure of disease progression in ambulatory
Morquio A patients. Growth likely inﬂuences the longitudinal patterns
of change in respiratory function, as FVC andMVVparameters increased
in younger patients but decreased in older patients. Longer duration of
follow-up will be required to elucidate the natural history of Morquio
A syndrome.
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